Trial · NCT01914965
Apathy Cure Through Bupropion in Huntington's Disease
NCT01914965, Phase 2, Completed, Charite University, Berlin, Germany
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Apathy Cure Through Bupropion in Huntington's Disease. Trials, record NCT01914965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01914965
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Apathy Cure Through Bupropion in Huntington's Disease
- NCT number
- NCT01914965
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- Charite University, Berlin, Germany
- Conditions
- Apathy, Huntington's Disease
- Interventions
- Bupropion, Placebo
- First posted
- 2013-08-02
- Last updated
- 2014-09-09
- Other registries' IDs
- eudract:2009-013698-16
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Apathy Evaluation Scale (AES-I) | 10 weeks | The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I \[informant\] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment. |
| Secondary | AES-C (clinician) | 10 weeks | The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-C, where C \[clinician\] is the trial investigator) in patients with HD after ten weeks of treatment. |
| Secondary | AES-S (self) | 10 weeks | The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-S, where S \[self\] is the patient) in patients with HD after ten weeks of treatment. |
| Secondary | Motor symptoms (UHDRS) | 10 weeks | The influence of Bupropion compared to placebo on the UHDRS motor score in patients with HD after ten weeks of treatment. |
| Secondary | Quantitative grip force motor assessment | 10 weeks | The influence of Bupropion compared to placebo on motor scores in patients with HD after ten weeks of treatment. |
| Secondary | Cognitive Symptoms | 10 weeks | The influence of Bupropion compared to placebo on MMSE in patients with HD after ten weeks of treatment. |
| Secondary | Psychiatric symptoms | 10 weeks | The influence of Bupropion compared to placebo on UHDRS behavioural assessment in patients with HD after ten weeks of treatment. |
| Secondary | Activities of daily living | 10 weeks | The influence of Bupropion compared to placebo on UHDRS Functional Assessment in patients with HD after ten weeks of treatment. |
| Secondary | Caregiver's distress | 10 weeks | The influence of Bupropion compared to placebo on the NPI caregiver's distress score. |
| Secondary | ventral striatal and ventromedial prefrontal activation | 10 weeks | Change of ventral striatal and ventromedial prefrontal activation in response to a reward paradigm as quantified by fMRI. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01914965
GET https://conductscience.org/api/trials/v1/NCT01914965/registered